Congress Materials – The Professional Society for Health Economics and Outcomes Research (ISPOR 2026)
Congress Materials – The Professional Society for Health Economics and Outcomes Research (ISPOR 2026)
2026 The Professional Society for Health Economics and Outcomes Research | May 17-20 | Philadelphia, PA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
CONCENTRATION OF 340B PROGRAM EXPANSION AMONG HOSPITALS OF VARYING SIZE: A RETROSPECTIVE ANALYSIS, 2017-2023
Neal Masia, Ulrich Neumann, Silas Martin
PERSPECTIVE MISMATCH AND STATIC ASSUMPTIONS: RE-THINKING HOW DRUG PRICES ARE SPECIFIED IN U.S. ECONOMIC ANALYSES
Michael Willis, Andreas Nilsson, Cheryl Neslusan
THE EXTENT OF TREATMENT RESPONSE AND PREFERENCE HETEROGENEITY IN MAJOR DEPRESSIVE DISORDER: IMPLICATIONS FOR POPULATION-LEVEL RESOURCE ALLOCATION
Jason Shafrin, Nadine Zawadzki, Cheryl Neslusan
THE NEED TO CONSIDER THE IMPACT OF DRIVERS OF RELATIVE TREATMENT EFFECTS BEYOND TREATMENT CHOICE IN COST-EFFECTIVENESS ANALYSES (CEA)
Warren Stevens, Lela Krackow, Cheryl Neslusan
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.